Publication:
Development of biological tools to assess the role of TMPRSS4 and identification of novel tumor types with high expression of this prometastatic protein

Simple item page
dc.contributor.authorVillalba, Maria
dc.contributor.authorLopez, Lissett
dc.contributor.authorRedrado, Miriam
dc.contributor.authorRuiz, Tamara
dc.contributor.authorde Aberasturi, Arrate L.
dc.contributor.authorde la Roja, Nuria
dc.contributor.authorGarcia, David
dc.contributor.authorExposito, Francisco
dc.contributor.authorde Andrea, Carlos
dc.contributor.authorÁlvarez Fernández, Emilio
dc.contributor.authorMontuenga, Luis
dc.contributor.authorRueda, Paloma
dc.contributor.authorRodriguez, Maria Jose
dc.contributor.authorCalvo, Alfonso
dc.date.accessioned2022-03-03T12:12:46Z
dc.date.available2022-03-03T12:12:46Z
dc.date.issued2017
dc.description.abstractMetastatic spread is responsible for the majority of cancer deaths and identification of metastasisrelated therapeutic targets is compulsory. TMPRSS4 is a pro-metastatic druggable transmembrane type II serine protease whose expression has been associated with the development of several cancer types and poor prognosis. To study the role and expression of this protease in cancer, we have developed molecular tools (active recombinant proteins and a polyclonal antibody) that can be used for diagnostic purposes and for testing anti-TMPRSS4 drugs. In addition, we have evaluated TMPRSS4 protein expression in several cancer tissue microarrays (TMAs). Full length and truncated TMPRSS4 recombinant proteins maintained the catalytic activity in two different expression systems (baculovirus and E. coli). Sensitivity of the rabbit polyclonal antisera against TMPRSS4 (ING-pAb) outperformed the antibody most commonly used in clinical settings. Analysis by immunohistochemistry in the different TMAs identified a subset of adenocarcinomas, squamous carcinomas, large cell carcinomas and carcinoids of the lung, in which TMPRSS4 expression may define aggressive tumors. In conclusion, our biological tools will help the characterization of TMPRSS4 activity and protein expression, as well as the evaluation of anti-TMPRSS4 drugs. Future studies should determine the clinical value of assessing TMPRSS4 levels in different types of lung cancer.es
dc.formatapplication/pdfes
dc.format.extent12es
dc.identifier.citationHistology and Histopathology, Vol.32, nº9, (2017)
dc.identifier.doiDOI: 10.14670/HH-11-857
dc.identifier.issn1699-5848
dc.identifier.issn0213-3911
dc.identifier.urihttp://hdl.handle.net/10201/117567
dc.languageenges
dc.publisherUniversidad de Murcia. Departamento de Biología Celular e Histologíaes
dc.relationSin financiación externa a la Universidades
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectTMPRSS4es
dc.subjectRecombinant proteinses
dc.subjectSquamous lung carcinomases
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncologíaes
dc.titleDevelopment of biological tools to assess the role of TMPRSS4 and identification of novel tumor types with high expression of this prometastatic proteines
dc.typeinfo:eu-repo/semantics/articlees
dspace.entity.typePublicationes
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Villalba-32-929-940-2017.pdf
Size:
11.3 MB
Format:
Adobe Portable Document Format
Description:
Download
License bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
license.txt
Size:
1.39 KB
Format:
Item-specific license agreed upon to submission
Description:
Download
Collections
Histology and histopathology Vol.32, nº9 (2017)